GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » EBIT

ME Therapeutics Holding (XCNQ:METX) EBIT : C$-6.93 Mil (TTM As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding EBIT?

ME Therapeutics Holding's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2024 was C$-0.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-6.93 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ME Therapeutics Holding's annualized ROC % for the quarter that ended in Feb. 2024 was -1,731.34%. ME Therapeutics Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -4,237.04%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ME Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -6.90%.

ME Therapeutics Holding EBIT Historical Data

The historical data trend for ME Therapeutics Holding's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding EBIT Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
EBIT
-0.14 -6.51

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
EBIT Get a 7-Day Free Trial -0.06 -3.50 -2.95 -0.34 -0.14

Competitive Comparison of ME Therapeutics Holding's EBIT

For the Biotechnology subindustry, ME Therapeutics Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's EV-to-EBIT falls into.


ME Therapeutics Holding EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding  (XCNQ:METX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ME Therapeutics Holding's annualized ROC % for the quarter that ended in Feb. 2024 is calculated as:

ROC % (Q: Feb. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2023 ) + Invested Capital (Q: Feb. 2024 ))/ count )
=-0.58 * ( 1 - 0% )/( (0.05 + 0.017)/ 2 )
=-0.58/0.0335
=-1,731.34 %

where

Invested Capital(Q: Nov. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.471 - 0.039 - ( 0.382 - max(0, 0.079 - 0.471+0.382))
=0.05

Invested Capital(Q: Feb. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.364 - 0 - ( 1.347 - max(0, 0 - 1.363+1.347))
=0.017

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

ME Therapeutics Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2023  Q: Feb. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.572/( ( (0 + max(0.019, 0)) + (0 + max(0.008, 0)) )/ 2 )
=-0.572/( ( 0.019 + 0.008 )/ 2 )
=-0.572/0.0135
=-4,237.04 %

where Working Capital is:

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.058) - (0.039 + 0 + 0)
=0.019

Working Capital(Q: Feb. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.008) - (0 + 0 + 0)
=0.008

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ME Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2024 )
=-6.928/100.416
=-6.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding EBIT Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » EBIT
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines